A first-in-class drug candidate, the soluble receptor fragment of VEGFR-3 named OPT-302 (VEGFR-3D1-3 fused to the Fc fragment of IgG1), is explored in clinical trials to target VEGF-C and VEGF-D, as monotherapy or combined with VEGF-A blockade, in eye diseases such as neovascular AMD [149]. Here, VEGFA is linked to eye disorder.